PMEL17 / GP100 Antibody
Rabbit mAb
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB, IHC |
---|---|
Primary Accession | P40967 |
Clonality | Monoclonal |
Other Names | PMEL; ME20-M; Premelanosome protein; Silver locus protein homolog; PMEL17; SILV; |
Isotype | Rabbit IgG |
Host | Rabbit |
Calculated MW | 70255 Da |
Dilution | WB 1:500~1:2000 IHC 1:50~1:200 |
---|---|
Purification | Affinity-chromatography |
Immunogen | A synthesized peptide derived from human PMEL17 / GP100 |
Description | Plays a central role in the biogenesis of melanosomes. Involved in the maturation of melanosomes from stage I to II. The transition from stage I melanosomes to stage II melanosomes involves an elongation of the vesicle, and the appearance within of distinct fibrillar structures. Release of the soluble form, ME20-S, could protect tumor cells from antibody mediated immunity. |
Storage Condition and Buffer | Rabbit IgG in phosphate buffered saline , pH 7.4, 150mM NaCl, 0.02% sodium azide and 50% glycerol. Store at +4°C short term. Store at -20°C long term. Avoid freeze / thaw cycle. |
Name | PMEL |
---|---|
Synonyms | D12S53E, PMEL17, SILV |
Function | Forms physiological amyloids that play a central role in melanosome morphogenesis and pigmentation. The maturation of unpigmented premelanosomes from stage I to II is marked by assembly of processed amyloidogenic fragments into parallel fibrillar sheets, which elongate the vesicle into a striated ellipsoidal shape. In pigmented stage III and IV melanosomes, the amyloid matrix serves as a platform where eumelanin precursors accumulate at high local concentrations for pigment formation. May prevent pigmentation-associated toxicity by sequestering toxic reaction intermediates of eumelanin biosynthesis pathway. |
Cellular Location | Endoplasmic reticulum membrane; Single-pass type I membrane protein. Golgi apparatus, cis-Golgi network membrane; Single-pass type I membrane protein. Endosome, multivesicular body. Melanosome Extracellular vesicle. Secreted. Note=Identified by mass spectrometry in melanosome fractions from stage I to stage IV (PubMed:17081065) Localizes predominantly to intralumenal vesicles (ILVs) within multivesicular bodies. Associates with ILVs found within the lumen of premelanosomes and melanosomes and particularly in compartments that serve as precursors to the striated stage II premelanosomes (PubMed:11694580, PubMed:12643545). Sorted to stage I melanosomes following its processing in the ER and cis-Golgi (PubMed:15096515) Transiently expressed at the cell surface before targeting to early melanosomes (PubMed:16760433, PubMed:30988362). Colocalizes with BACE2 in stage I and II melanosomes (PubMed:23754390). Colocalizes with CD63 and APOE at exosomes and in intraluminal vesicles within multivesicular endosomes (PubMed:21962903, PubMed:26387950) |
Tissue Location | Normally expressed at low levels in quiescent adult melanocytes but overexpressed by proliferating neonatal melanocytes and during tumor growth. Overexpressed in melanomas. Some expression was found in dysplastic nevi. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.